Influenza Diagnostics Market Size To Hit US$ 3.1 Billion By 2033, Owing To Increasing Investments in Healthcare Sector Globally | Persistence Market Research
March 23, 2023 22:20 ET
|
Persistence Market Research
New York, March 23, 2023 (GLOBE NEWSWIRE) -- The Influenza Diagnostics Market to reach a valuation of US$ 1.6 Billion in 2022 to US$ 3.1 Billion by the end of 2033, with at a CAGR of 6.1%. ...
Influenza Diagnostics Market Forecast to Accrue USD 1.15 Billion by 2027 | Increasing Need For Rapid And Accurate Testing will be the Major Factor Driving the Industry Growth, says Reports and Data
January 27, 2021 17:00 ET
|
Reports and Data
New york, Jan. 27, 2021 (GLOBE NEWSWIRE) -- The global influenza diagnostics market is predicted to accrue nearly USD 1.15 Billion by 2027, registering a significant CAGR of 7.7%. Revenue from this...
Interpace Diagnostics to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results on Tuesday, August 13, 2019
August 06, 2019 16:05 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it will report its second quarter 2019 financial results on Tuesday, August...
Interpace Diagnostics Announces Pricing of $7.0 Million Public Offering of Common Stock
January 25, 2019 06:00 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, N.J., Jan. 25, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (Nasdaq: IDXG) (“Interpace” or the “Company”) today announced the pricing of an underwritten public offering of...
Interpace Diagnostics Announces Participation at the DJCON18
October 24, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
Including Participation in the Panel on the Impact of AI and Bioinformatics in Healthcare PARSIPPANY, NJ, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...
Interpace Diagnostics Enters into Agreement with Renowned Integrated Health System
October 04, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
Agreement with Piedmont Healthcare Covers Company’s Pancreatic Cancer Test PARSIPPANY, NJ, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) reported today that it has...
Interpace Diagnostics to Present New Data at the 88th Annual Meeting of the American Thyroid Association (ATA) on October 5th
October 01, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
ThyGenX® and ThyraMIR® Data from Clinical Experience Study to be Featured at ATA Product Expo PARSIPPANY, NJ, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...
Interpace Diagnostics Announces Reimbursement Expansion of ThyGeNEXT™
September 24, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
State of Pennsylvania and New York Approve Commercialization of New Thyroid Cancer Test PARSIPPANY, NJ, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG), announced...
Interpace Diagnostics Supports Research Efforts of Pancreatic and Thyroid Cancer Patient Advocacy Groups
September 17, 2018 08:30 ET
|
Interpace Diagnostics Group, Inc.
Interpace Employees Participate in Local Events in Support of Lustgarten Foundation for Pancreatic Cancer Research, Thyroid, Head and Neck Cancer Foundation, and Pancreatic Cancer Action Network ...
Interpace Diagnostics Acquires Select Assets of Rosetta Genomics Out of Bankruptcy
August 15, 2018 08:30 ET
|
Interpace Diagnostics Group, Inc.
Several Former Rosetta Employees and Select Customers Also Join Interpace Parsippany, NJ, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the...